Showing results (131-140 of 148) with videos related to
Sort By:
Pageof 15
Journal of Clinical Medicine|September 23, 2022
Evaluation of a Triage Checklist for Mild COVID-19 Outpatients in Predicting Subsequent Emergency Department Visits and Hospitalization during the Isolation Period: A Single-Center Retrospective StudyYasuhiro Tanaka, Kazuko Yamamoto, Shimpei Morimoto, et al.Journal of Clinical Medicine|February 26, 2025
Prospective Survey of Postoperative Pain in Japan: A Multicenter, Observational StudyMasaki Kaibori, Kengo Yoshii, Tung Thanh Lai, et al.Liver International : Official Journal of the International Association for the Study of the Liver|July 7, 2025
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and BevacizumabTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.Liver International : Official Journal of the International Association for the Study of the Liver|June 25, 2025
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre StudyTakeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.Liver Cancer|October 9, 2025
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular CarcinomaKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.Oncology|August 10, 2025
Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular CarcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter studyAtsushi Naganuma, Satoru Kakizaki, Takeshi Hatanaka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 6, 2025
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective AnalysisTakeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.Journal of Gastroenterology|August 20, 2025
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Cancer Medicine|February 15, 2026
Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical PracticeHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Pageof 15